To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers
Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :
It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).
Two teams at SPI (DMTS) have identified by mass spectrometry several biomarkers related to cognitive improvement in mouse models presenting the clinical characteristics of patients with creatine transporter deficiency, treated with a dodecyl creatine ester.
A Li2D (SPI/DMTS) team used tandem mass spectrometry to identify microorganisms in sputum samples from cystic fibrosis patients. A promising proteotyping approach that provides an expanded and unbiased view of the cystic fibrosis microbiota and could be complementary to microbiological monitoring of patients.
A SIMoS team discovered a toxin in the venom of a marine cone that it engineers into a high affinity antagonistic peptide for the melanocortin receptor, a major regulator of energy homeostasis. A step towards the development of innovative treatments for certain eating disorders
Researchers at the Joliot Institute have developed two new families of iminosydnones that allow the bio-orthogonal release of electrophilic species. These molecules constitute "building blocks" of click-and-release chemistry, useful for reactions with nucleophilic compounds contained in cells.
A Li2D team has released the peptidomic profile of the virus that causes monkeypox, which they established using tandem mass spectrometry. These data should help to better understand the evolution of the epidemic and allow the creation of targeted tests to potentially detect the threat more quickly and prevent a new epidemic.
A consortium of researchers, including SPI/DMTS metabolomics specialists, presents PeakForest, a database of NMR and mass spectra, which provides storage and annotation services for spectra of reference compounds and metabolic profiles of biological matrices. An open resource to address the evolving needs of the discipline.
A team from SIMoS (DMTS) identifies and characterizes a toxin isolated from black mamba venom, whose specific anticholinergic properties at the type 2 acetylcholine receptor, a regulator of arterial tone, position it as a potential drug candidate for the treatment of cardiovascular diseases.
To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified
IBiSA, within the Frédéric Joliot Institute for Life Sciences:
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.